Health & Nutrition Systems International expects to book revenue by the end of March from its January acquisition of three Acutrim trademarks and outstanding inventory of two natural "ephedrine-free" appetite suppressant formulations for $180,000 from Heritage Brands/Insight Pharmaceuticals. West Palm Beach, Fla.-based HNS, which markets weight management and body building products such as Carb Cutter, Thin Tab and Carbolizer in gyms, health food stores and drug chains, purchased only the inventory for Acutrim Natural A.M. and P.M., which launched last June (1"The Tan Sheet" May 15, 2000, p. 7). Heritage pulled original Acutrim formulas from the market after FDA's November request that companies voluntarily halt marketing PPA-containing products. The Acutrim franchise has lost market share in recent years to ephedrine alkaloid-containing supplements
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.
Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.
Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.
